Avalyn Pharma
Avalyn Pharma develops inhaled therapies for severe respiratory diseases, including its lead candidate AP01 for treating pulmonary fibrosis.
Secondary Market Price
How Avalyn Pharma Measures Up
To help you manage your Avalyn Pharma equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Avalyn Pharma's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Avalyn Pharma Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Avalyn Pharma's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Avalyn Pharma is a biopharmaceutical company that develops inhaled therapies for severe respiratory diseases, with a focus on pulmonary fibrosis and other interstitial lung diseases. The company’s approach is to reformulate approved oral medicines into inhaled treatments that can be delivered directly into the lungs, with the goal of improving tolerability and efficacy. Its lead candidate, AP01, is an inhaled formulation of pirfenidone that is currently in a global Phase 2b study. Avalyn's pipeline also includes AP02, an inhaled version of nintedanib that has completed two Phase 1 studies. Founded in 2011, the company is headquartered in Cambridge, Massachusetts.
The company plans to initiate a Phase 2 clinical trial for AP02 in 2026 and is advancing the development of AP03, a novel fixed-dose combination of pirfenidone and nintedanib. Recent developments include the publication of the design for its AP01 Phase 2b MIST clinical trial in BMJ Open Respiratory Research. To support its programs, Avalyn Pharma raised $100 million in a Series D funding round in August 2025, led by investors including Suvretta Capital Management and SR One.
- Perceptive Xontogeny Venture Funds
- SR One
- Eventide Asset Management
- Vida Ventures
- Wellington Management
- Rock Springs Capital
- T. Rowe Price Associates
- Surveyor Capital
- Catalio Capital Management
- Piper Heartland
- Novo Holdings A/S
- Norwest Venture Partners
- F-Prime Capital
- Pivotal bioVenture Partners
- RiverVest Venture Partners
- Suvretta Capital Management
- TPG Biotech
- Hamilton Square Partners Management
- HSq
- Co-Founder, Mark Surber
- Co-Founder, Bruce Montgomery
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Avalyn Pharma worth joining?
Deciding whether to join any startup requires a careful evaluation of its financial health, growth prospects, and the specifics of your compensation package. Tools like Prospect can help you model the potential future value of your equity offer to make a more informed decision.
What should I do with my Avalyn Pharma stock?
Managing your private company stock involves creating a strategy for exercising options and planning for potential tax implications. Platforms like Prospect can provide personalized option exercise strategies to help you optimize your equity and maximize its after-tax value.
Can you sell Avalyn Pharma stock?
Selling stock in a private company like Avalyn Pharma is often possible through secondary markets or company-organized tender offers, though restrictions may apply. Prospect offers tender offer tools to help you determine the tax-optimal shares to sell when an opportunity arises.
How can I find the value of my Avalyn Pharma stock?
The value of private stock isn't publicly listed and is typically based on the company's latest 409A valuation or secondary market trades. To get a better sense of its potential future worth, you can use platforms like Prospect, which use predictive models to forecast your equity's value.
What is Avalyn Pharma's equity worth?
As a private company, Avalyn Pharma's total equity valuation is not public information and is determined by factors like its most recent funding round. You can use tools from Prospect to model different scenarios and project the potential value of your specific holdings.
What is Avalyn Pharma's stock ticker symbol?
Avalyn Pharma is a private company, so it does not have a stock ticker symbol and is not traded on public stock exchanges. Ticker symbols are assigned to companies only when they become publicly listed through an Initial Public Offering (IPO).
Can I buy or sell Avalyn Pharma stock?
As Avalyn Pharma is a private company, its stock is not available on public exchanges, and buying shares is typically limited to accredited investors or employees. Selling your shares may be possible through secondary markets or tender offers, but this is subject to company policies and market demand.
What is the criteria to buy or invest in Avalyn Pharma stock?
Investing in a private company like Avalyn Pharma is generally restricted to accredited investors who meet specific income or net worth requirements set by regulators. Employees may also acquire stock by exercising their stock options as part of their compensation.
